Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections-Reference-Cited by-同舟云学术

Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections

Published:2016-04-27 Issue:4 Volume:194 Page:687-697
ISSN:0341-2040
Container-title:Lung
language:en
Short-container-title:Lung

Author:

Koatz Ana M.,Coe Noemí A.,Cicerán Alberto,Alter Adriana J.

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00408-016-9880-5.pdf

Reference42 articles.

1. Anand VK (2004) Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 193:3–5

2. Bosch AA, Biesbroek G, Trzcinski K et al (2013) Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog 9:e1003057

3. Chang LH, Rivera MP (2013) Respiratory diseases: meeting the challenges of screening, prevention, and treatment. N C Med J 74:385–392

4. Schaad U, Principi N (2012) The management of recurrent respiratory tract infections in children. Eur Infect Dis 6:111–115

5. West JV (2002) Acute upper airway infections. Br Med Bull 61:215–230

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Postbiotics in Asthma Treatment;Microorganisms;2024-08-11

2. Broncho-Vaxom Attenuates Lipopolysaccharide-Induced Inflammation in a Mouse Model of Acute Lung Injury;International Journal of Molecular Sciences;2024-06-28

3. Immune Dysregulation in Chronic Obstructive Pulmonary Disease;Immunological Investigations;2024-04-04

4. MicroRNA-155 is a critical regulator of regulatory T cells in OM-85 Broncho-Vaxom treated experimental models of allergic rhinitis;AIMS Allergy and Immunology;2024

5. Short-term administration of Qipian®, a mixed bacterial lysate, inhibits airway inflammation in ovalbumin-induced mouse asthma by modulating cellular, humoral and neurogenic immune responses;Life Sciences;2024-01